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In the current issue of the Korean Jour-
nal of Internal Medicine, Choi et al. [1] 
present a number of notable findings. 
In an analysis of > 80,000 Korean sub-
jects newly diagnosed with atheroscle-
rotic cardiovascular disease (ASCVD), 
about 60% received lipid-lowering 
therapy (LLT) during the follow-up 
period. While statins were prescribed 
for 80% of patients with coronary 
artery disease (CAD), 50% and 47% of 
those with cerebrovascular disease and 
peripheral artery disease took statins, 
respectively. Statin-based LLT was 
most frequently given at a moderate 
intensity. Factors such as age of both 
extremes, female sex, and comorbid-
ities were associated with less use of 
LLT [1].
The study by Choi et al. [1] provides 
valuable data regarding LLT in re-
al-world practice in Korea. In partic-
ular, they reveal that a considerable 
number of patients (even those with 
ASCVD) did not receive LLT after the 
diagnosis of this high-risk condition. 
However, because the study analyzed 
patient data collected between 2011 
and 2012, it is difficult to say that it ac-
curately reflects contemporary use of 
LLT. It is possible that a greater num-
ber of physicians are now prescribing 
statins, including high-dose statins, for 
high-risk patients according to updat-
ed international guidelines [2,3]. Thus, 
if the authors had included patients 
after the mid-2010s, the rate of statin 
use might have been higher. A few 
studies have described the rates of LLT 
or its results in Koreans with ASCVD 
or high cardiovascular risk [4-6]. One 
study of patients with acute myocardi-
al infarction from 2005 to 2011 showed 
a 77% to 83% statin prescription rate at 
discharge from the hospital [5]. Mean-
while, a study analyzing Koreans with 
CAD from 2013 to 2014 showed that 
91% of patients with stable CAD were 
receiving statin therapy [6]. In this re-
gard, we recognize that the rate of LLT 
in patients with ASCVD may differ by 
factors such as clinical presentation or 
the time point at which the patients 
were enrolled. 
In fact, the LLT intensity or target 
low-density lipoprotein cholesterol 
(LDL-C) levels rather than decision 
to use LLT in patients with ASCVD is 
a matter of great interest in current 
practice. Additional issues include 
selecting candidates and the appro-
priate strength of LLT in populations 
without ASCVD. I will not discuss 
the second issue, as it is beyond the 
scope of the current editorial and is 
more controversial. The latest Amer-
ican and European guidelines for 
LLT specify LDL-C targets of < 70 or 
< 55 mg/dL for very high-risk groups 
(like the patients analyzed by Choi et 
al. [1]) [2,3]. These recommendations 
are largely based on “the greater the 
risk, the greater the benefit,” a cen-
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tral principle of LLT (Fig. 1) [7]. In particular, since 
2016, European guidelines have suggested lowering 
the LDL-C level to a specific target while achieving a 
≥ 50% reduction in LDL-C for very high-risk patients. 
The idea is to avoid insufficient LLT in patients with 
ASCVD and a low baseline LDL-C level. In these pa-
tients, lowering the LDL-C level to < 70 mg/dL (but 
without a ≥ 50% reduction) using low- or moderate-in-
tensity statins may deny them the potential outcome 
benefit that could be obtained if they were treated 
with high-intensity statins. 
Choi et al. [1] also showed that the rates of LLT were 
lower in patients with cerebrovascular disease or periph-
eral artery disease than in those with CAD. However, for 
cerebrovascular disease, they did not differentiate hem-
orrhagic from ischemic disease. Had they analyzed isch-
emia-related cerebrovascular disease separately, we may 
have been provided with further insight into this issue. 
Older patients received statins less frequently in this 
study [1]. It has long been argued whether statin ther-
apy has equivalent value in older people. Older people 
with a high cardiovascular risk need active LLT, but 
they also have a greater risk of experiencing adverse 
events. Sometimes, the outcome benefit of LLT can 
be unclear due to the shorter life expectancy of older 
patients. However, statins are beneficial for second-
ary prevention, even in older adults [8]. Furthermore, 
recent data from Koreans aged > 75 years indicate that 
older individuals can obtain a clinical benefit from 
LLT for primary prevention [9]. Therefore, it is im-
portant to use statins in older patients for secondary 
prevention.
As expected, most Korean physicians prescribe mod-
erate-intensity statins. This has been demonstrated 
in multiple studies of Koreans, regardless of the pres-
ence of ASCVD [9,10]. The practice of LLT in Korea 
appears to be conforming to updated domestic and 
international guidelines. However, a few issues must 
be addressed. As proposed by Choi et al. [1], some 
physicians dislike high-dose statins and so may not 
prescribe them. This may prevent patients with ASC-
VD from receiving sufficient benefit from treatment; 
indeed, patients with ASCVD can receive a greater 
absolute benefit from LLT than any other group of 
patients. Common errors also include prescribing an 
inappropriate dose of statins or overusing combina-
tion therapy with statins and ezetimibe in lower risk 
groups. 
It remains to be determined what the optimal statin 
dose is and what the optimal targets are (if they exist) 
for LDL-C in diverse cardiovascular risk groups in Ko-
rea. Although the work of Choi et al. [1] contributes to 
our knowledge of LLT in Korean patients, additional 
studies by active scholars are needed on this greatest 
possible preventive measures for cardiovascular disease. 
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